Sitero Acquires Clario's eClinical Technology Suite
Sitero has announced its recent acquisition of a technology suite designed to manage the end-to-end clinical trial lifecycle. The newly acquired eClinical technology suite, formerly of Clario, will be integrated with Sitero's existing Mentor platform with plans to invest in AI to further streamline the clinical trial process. This combined suite offers tools designed to enhance efficiency, accuracy, and quality of data across the site, CRO, and sponsor lifecycle of clinical trials.
Key components of the technology platform include:
- Electronic Data Capture (EDC) and System
- Randomization and Trial Supply Management (RTSM)
- Clinical Trial Management System (CTMS)
- eTMF
- eConsent
- Site and Patient Payments
The Clario eClinical product suite will be rebranded and integrated into the Sitero Mentor platform. Sitero Mentor will continue to support the existing Clario customer base while further developing clinical solutions for new customers as well.
Reference
Sitero Acquires Clario's eClinical Technology Suite to Enhance Clinical Trial Delivery. (2023, August 1). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
